Research & Advanced Technologies


The metabolism of T3 and T4 combination therapy into active and inactive intermediates involves the action of 3 types of deiodinases. Recent studies of common genetic variations in deiodinase and thyroid hormone transport proteins offer fresh insights in understanding the variable response to thyroid hormone therapy and future research may clarify whether subsets of patients will benefit from challenges and improvements to combination therapy. Despite significant challenges, opportunities abound for improving the Thyroid Treatment Augments Psychiatric Therapy and also Improvements of Reproductive, Neuro-endocrinology or Neuroendocrine Function in Hypothalamic.

 

  • type 1 diabetes risk.
  • Understanding the biology of body-weight regulation in children.
  • Molecule to improve continuous glucose monitoring.
  • Legacy effect of diabetes
  • Insulin-producing beta-cells

Related Conference of Research & Advanced Technologies

September 09-10, 2024

7th Annual Meeting on Diabetes and Endocrinology

Paris, France
September 09-10, 2024

33rd International Diabetes and Healthcare Conference

Paris, France
September 09-10, 2024

4th European Endocrinology and Diabetes Congress

Paris, France
September 25-26, 2024

5th World Summit on Diabetes Expo

Rome, Italy
October 14-15, 2024

3rd International Summit on Hormonal Disorders

Madrid, Spain
November 22-23, 2024

20th World Congress on Endocrinology & Diabetes

Amsterdam, Netherlands
February 24-25, 2025

34th European Diabetes Congress

London, UK
March 10-11, 2025

Euro Endocrinology 2025

Rome, Italy

Research & Advanced Technologies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in